Glioblastoma with Primitive Neuroectodermal Component Treated with Adjuvant Radiotherapy and Temozolomide: A Pooled...

Area of Science:

• Neuro-oncology
• Central Nervous System Tumors
• Cancer Histopathology

Background:

• Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis.
• GBM with neuroectodermal differentiation (GBM-PNET) is a recently identified subtype.
• The neuroectodermal component may increase the risk of systemic spread.

Purpose of the Study:

• To analyze the treatment patterns and outcomes for GBM-PNET.
• To compare the clinical behavior of GBM-PNET with conventional GBM.

Main Methods:

• Retrospective analysis of four GBM-PNET cases treated at the institute.
• Literature review and pooled analysis of 23 additional GBM-PNET cases.
• Evaluation of treatment modalities including surgery, radiotherapy, and chemotherapy (temozolomide).

Main Results:

• Four GBM-PNET patients received surgery, radiotherapy, and temozolomide; one experienced local recurrence.
• Pooled analysis of 23 patients showed median progression-free survival of 10 months and overall survival of 25 months.
• Extent of surgery, radiation technique, and age did not significantly impact survival.

Conclusions:

• GBM-PNET is a rare entity with clinical behavior and outcomes comparable to conventional GBM.
• Patients with GBM-PNET face an elevated risk of cerebrospinal fluid (CSF) dissemination.
• An individualized treatment strategy is crucial for managing GBM-PNET.